XBiotech Inc.

For the period ended Dec 31, 2025. Filed Mar 13, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 13, 2026

XBIT$1.91+1.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share data)

	December 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$125,551	$172,677
Accrued interest receivable	360	700
Income tax receivable	-	158
Prepaid expenses and other current assets	1,042	1,032
Total current assets	126,953	174,567
Property and equipment, net	23,129	24,526
Total assets	$150,082	$199,093
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	$1,535	$2,223
Accrued expenses	6,318	2,632
Income tax payable	76	-
Convertible loan, related party	-	10,000
Convertible loan, third party	-	250
Total current liabilities	7,929	15,105
Long-term liabilities:
Income tax payable	1,798	1,720
Deferred tax liability	5	-
Total liabilities	9,732	16,825
Shareholders’ equity:
Preferred stock, no par value, unlimited shares authorized, no shares outstanding	-	-
Common stock, no par value, unlimited shares authorized, 30,487,731 share issued and outstanding at December 31, 2025 and December 31, 2024	276,727	273,105
Accumulated deficit	(136,377)	(90,837)
Total shareholders’ equity	140,350	182,268
Total liabilities and shareholders’ equity	$150,082	$199,093

See accompanying notes to consolidated financial statements.

XBiotech Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.